Elisabeth Silkenstedt

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Dna Damage Response

Acute Lymphoblastic Leukemia

Diffuse Large B Cell Lymphoma

Top Venues

Hematological oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Elisabeth Silkenstedt, Martin Dreyling
Treatment of Relapsed/Refractory MCL. Blood (2024)
Katrin S Kurz, Elisabeth Silkenstedt, Martin Dreyling, Sílvia Beà
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Blood advances 8 (14) (2024)
Katrin S Kurz, Elisabeth Silkenstedt, Martin Dreyling, Sílvia Beà
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Blood advances 8 (14) (2024)
Katrin S Kurz, Elisabeth Silkenstedt, Martin Dreyling, Sílvia Beà
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Blood advances 8 (14) (2024)
Katrin S Kurz, Elisabeth Silkenstedt, Martin Dreyling, Sílvia Beà
Biological and Clinical Determinants Shaping Heterogeneity in Mantle Cell Lymphoma. Blood advances (2024)
Elisabeth Silkenstedt, Martin Dreyling
Treatment of Relapsed/Refractory MCL. Blood (2024)
Marie Moosburner, Lamija Alibegovic, Korbinian Hasselmann, Anton Gaiderov, Johannes Hildebrand, Julia Philippou-Massier, Helmut Blum, Luca Fischer, Martin Dreyling, Elisabeth Silkenstedt
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus. Hematological oncology (2023)